A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients

NCT05671315 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

267

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis B
Intermediate to High Risk of HCC

Interventions

DRUG: Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue
DRUG: Nucleos(t)ide analogue

Sponsor

Qing XIe